Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial - Henderson, E J; Lord, S R; Brodie, M A (Lancet Neurol, 2016)
et al.